Visit https://www.peervoice.com/YER860 to view the entire programme with slides. After completing “The Science of Weight Loss: Why “Eat Less, Move More” Fails and Why We Need to Do More”, participants will be able to: Describe unmet needs for patients with type 2 diabetes (T2DM) and obesity; Translate recent guideline updates for individualising management of T2DM and obesity; Explain safety and efficacy of pharmacologic options for the management of patients with T2DM and obesity, such as incretins.

Visit https://www.peervoice.com/CGV860 to view the entire programme with slides. After completing “The Need for Speed: Improving Diagnostic Accuracy and Effective Management of aTTP in Emergency and Intensive Care”, participants will be able to: Discuss the importance of efficient and effective identification and initiation of therapy in patients with suspected acquired thrombotic thrombocytopenic purpura (aTTP); Explain recent guidelines on diagnosis and initial management of patients with aTTP in the emergency department/intensive care unit (ED/ICU); Apply evidence- and expert-based guidance in the management of aTTP.

Visit https://www.peervoice.com/UHN860 to view the entire programme with slides. After completing “Seeking a More Positive Outlook in Patients With mTNBC? Treatment Advances and How to Apply Them”, participants will be able to: Describe the efficacy and safety data for recent treatment options for metastatic triple-negative breast cancer (mTNBC); Evaluate the clinical implications of the evidence for new treatments on real-life practices; Identify which patients are most likely to benefit from the new treatment options, such as the TROP2-directed antibody drug-conjugate (ADC) therapies.

Visit https://www.peervoice.com/GMF860 to view the entire programme with slides. After completing “Shifting the Treatment Paradigm in Type 2 Diabetes and CKD: The Role of Nonsteroidal MRAs”, participants will be able to: Evaluate recent clinical data for novel strategies for the management of type 2 diabetes (T2DM) and chronic kidney disease (CKD); Identify patient and disease characteristics that may influence treatment decision-making for patients with T2DM and CKD; Translate current and emerging clinical evidence into optimal treatment plans for patients with T2DM and CKD.

Visit https://www.peervoice.com/KAN860 to view the entire programme with slides. After completing “Raising the Bar in Heart Failure Management: 2021 Congress Updates on SGLT2 Inhibitors”, participants will be able to: Explain the most recent clinical evidence for SGLT2 inhibitors for the management of patients with heart failure (HF) and associated guidelines; Evaluate how these clinical data add to previous knowledge about the management of HF; Discuss the clinical implications of the guidelines and data in the context of current HF treatment paradigms.

Visit https://www.peervoice.com/XXB860 to view the entire programme with slides. After completing “A Multidisciplinary Approach to Prevention and Management of CKD in T2DM: Best Practices for Optimal Outcomes”, participants will be able to: Describe common challenges to multidisciplinary care for patients with type 2 diabetes (T2DM) who are suffering from, or at high risk of, chronic kidney disease (CKD); Analyse recent data for SGLT2 inhibitors and GLP-1 receptor agonists in the management of patients with T2DM and CKD; Propose strategies to improve communication and collaboration among the multidisciplinary team.

Visit https://www.peervoice.com/SDU860 to view the entire programme with slides. After completing “An Immune System in Double Trouble: What Is ‘Best Practice’ for Managing Patients With Lymphoproliferative Malignancies?”, participants will be able to: Describe the consequences of infectious complications on outcomes of patients with suspected secondary immunodeficiency (SID) due to a lymphoproliferative malignancy; Identify the predictive risk factors of an infectious complication occurring in patients with a lymphoproliferative malignancy that would warrant the need for supportive therapy; Apply practical strategies to monitor and manage infection risk in patients with lymphoproliferative malignancies.

Visit https://www.peervoice.com/FTG860 to view the entire programme with slides. After completing “The Holistic Care of Patients with T2DM: Going Beyond HbA1c”, participants will be able to: Discuss emerging clinical evidence for incretin therapies for type 2 diabetes (T2DM) and how these data may impact future management strategies; Describe the function of incretin hormones and their role in the pathogenesis of T2DM; Recognise the benefits of incretin therapies beyond glycaemic control in patients with T2DM; Apply best practices for the holistic management of patients with T2DM.

Visit https://www.peervoice.com/SCQ860 to view the entire programme with slides. After completing “Therapeutic Sequencing in Patients With Advanced or High Risk Hodgkin Lymphoma: Strategies in Action”, participants will be able to: Identify patient- and disease-related characteristics that might affect treatment selection for patients with Hodgkin lymphoma; Describe the rationale for evolving treatment strategies in patients with Hodgkin lymphoma; Assess the evidence for emerging treatment strategies for Hodgkin lymphoma.

Visit https://www.peervoice.com/HVG860 to view the entire programme with slides. After completing “Beyond Traditional MHT to Address Menopause Symptoms: A Shared Decision-Making Process”, participants will be able to: Outline key data and differences between traditional menopausal hormone therapy (MHT) and tissue selective estrogen complex (TSEC) to guide treatment selection for menopause symptoms.